Dapagliflozin preferentially reduces fibrosis biomarkers in chronic heart failure patients with high extracellular matrix remodeling activity
9 May 2026 (08:00 - 12:45)
Organised by: 

About the speaker

Biomedical Research Institute of Murcia (IMIB-Arrixaca), El Palmar, Murcia (Spain)
6 More presentations in this session
Doctor M. Badan (Chisinau, MD)
Access the full session
The Event
Heart Failure 2026
9 May - 12 May 2026
You may be interested in
Congress Session
